Translating mRNA
Educational Webinar Series
The Pfizer Vaccines US Medical Affairs Team invites you to attend an educational webinar series titled Translating mRNA which is focused on providing education on COVID-19 and vaccination. The webinar series is designed to communicate scientific information which may include recent study results to inform healthcare providers regarding Pfizer and BioNTech's COVID-19 vaccines.
The webinar series will include a live question-and-answer session with Pfizer medical experts.
We are hosting a Translating mRNA session on the topic below
Exploring Recent Data:
Pfizer Medical Affairs Updates on
COVID-19 from ACIP and More
Date and Time:
Thursday, 14 November 2024: 12:00 pm -12:30 pm EST
Speaker: Rajeev M Nepal, PhD
Medical Director, Pfizer mRNA Vaccines, Medical and Scientific Affairs, USA
Intended Audience: US healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants.
Continuing medical education credit is NOT associated with this event.
Indication and Usage
COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) in individuals 12 years of age and older.
Emergency use Authorization
Emergency uses of COVID-19 vaccines from BioNTech and Pfizer, including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula), have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 6 months of age and older. Emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical products under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
Please see EUA Fact Sheets at
www.cvdvaccine-us.com